Organizer can choose to mute himself – but I don’t think that was never the question. Since I was testing this on a single computer I turned off my audios for most of the time. However you cannot demote a organizer to attendee nor you can remove him from the meeting. If organizer wouldn’t have been muted already there would be a option to mute him. They can control the attendees as before – with the exception that there is the new function to promote a attendee to presenter or make a presenter to attendee. Also if you open the … menu you can see the recording is disabled but you can turn off incoming videos.Īttendees cannot mute others – they can only pin them.
When looking at the meeting bar the share control is disabled.
The AttendeeĪttendees have some options that are not available for them: What is good is that attendees cannot anymore take over the sharing and facilitation of the meetings is left to presenters. Organizer is the one who decides when it is a good moment to leave.Īttendees can enjoy the show, turn video on/off, mute or unmute themselves and use the Pin-option to choose the content they want to view the most. Presenters can mute the organizer, but there is no “remove participant” available. Presenters can do all that we have done in Teams meetings: they can share content, admit people in from a lobby, manage recording, mute or remove people from meetings. They are always in charge and can change who is a presenter or attendee. Organizer is a special role presenter that cannot be changed during the meeting nor anyone else can take it away. All meetings work in the same way -> whoever is scheduling or starting the meeting is the Organizer. I tested these in a scheduled meeting, meet now and in a channel meeting. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.If you have had a Teams meeting today, you may have noticed that you can now do changes who can present in Teams meetings!
Anyone with ms use the one minute cure trial#
Exhaustion affects CAR T–cell clinical responseĬlinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses.Researchers will present their work and share their expertise at ASH2021, the 63rd annual meeting of the American Society of Hematology. Jude at ASH: Annual hematology meeting highlights recent research Jude phase II clinical trial results suggest monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma. Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients.